

Applicants hereby elect the species of "atopic dermatitis", as recited in claim 35, with traverse.

The claims readable on the elected species are Claims 23-32. Claim 23 is generic.

Applicants respectfully traverse this requirement. The Office Action asserts that each site is associated with a different patient population, and because of this the methods directed to each site are patentably distinct. Applicants respectfully submit that many of the species recited in claims 33-38 are not patentably distinct for several reasons. Firstly, it is possible that a patient may have more than one species, e.g. psoriasis and lichen planus, or atopic dermatitis and inflamed tonsils, etc, and, as such, each site is not always associated with a different patient population. Secondly, many of the individual species are each readable upon each other. For example, sites of psoriasis, lichen plans, atopic dermatitis and tonsil inflammation can all be sites of chronic inflammation. Likewise, sites of psoriasis and atopic dermatitis can be sites of delayed hypersensitivity.

As such, the sites are not always associated with a different patient populations. Accordingly, applicants respectfully request that this species election requirement be withdrawn.

Applicants respectfully submit that the subject matter of these claims encompasses a reasonable number of species and that Claim 23 is generic to all the claimed species. As such, according to MPEP §809(c), Claim 23 should be examined by the Office if claims directed to the elected species are found allowable.


Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, Order No. STAN-110CON.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 13, 2003

By: _____


James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\STAN (Stanford)\110con\response to restriction requirement 9-24-2002.doc